Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$30.99
+1.1%
$30.02
$24.10
$62.53
$2.89B0.331.02 million shs1.14 million shs
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$12.71
+4.4%
$11.93
$5.00
$16.85
$720.46M1.51.59 million shs2.03 million shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
$19.50
$2.86B1.21.02 million shsN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$26.97
+1.4%
$32.75
$24.28
$55.33
$1.61B2.361.97 million shs1.20 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
+1.11%+0.23%+6.02%+1.31%-43.03%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
+4.35%+1.62%-1.16%+82.63%+79.03%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%0.00%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+1.43%-5.67%-22.34%-8.64%-38.94%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
3.6264 of 5 stars
3.40.00.03.73.62.50.0
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
1.0458 of 5 stars
1.23.00.00.02.62.50.6
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.8917 of 5 stars
3.42.00.04.42.90.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
2.78
Moderate Buy$68.86122.19% Upside
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
2.33
Hold$9.50-25.26% Downside
MorphoSys AG stock logo
MOR
MorphoSys
0.00
N/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.73
Moderate Buy$49.4083.17% Upside

Current Analyst Ratings Breakdown

Latest DNA, TWST, MOR, and CRNX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/25/2025
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSell ➝ Sell$6.00 ➝ $9.00
8/11/2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$90.00 ➝ $86.00
8/8/2025
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/4/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/4/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$46.00
7/10/2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$36.00
6/27/2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$81.00
(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$1.04M2,806.38N/AN/A$12.44 per share2.49
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$227.04M3.31N/AN/A$10.35 per share1.23
MorphoSys AG stock logo
MOR
MorphoSys
$238.28M11.99N/AN/A$0.35 per share54.17
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M5.20N/AN/A$7.92 per share3.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$298.41M-$4.11N/AN/AN/AN/A-32.28%-29.45%11/11/2025 (Estimated)
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$547.03M-$5.86N/AN/AN/A-136.56%-43.25%-22.29%11/11/2025 (Estimated)
MorphoSys AG stock logo
MOR
MorphoSys
-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$1.45N/AN/AN/A-23.51%-29.03%-21.77%11/17/2025 (Estimated)

Latest DNA, TWST, MOR, and CRNX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$1.13-$1.23-$0.10-$1.23$0.52 million$1.03 million
8/7/2025Q2 2025
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$1.44-$1.10+$0.34-$1.10$41.60 million$49.60 million
8/4/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54-$0.47+$0.07$0.33$95.52 million$96.06 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/AN/AN/AN/AN/A
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/A
17.80
17.80
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/A
5.41
5.41
MorphoSys AG stock logo
MOR
MorphoSys
4.98
1.38
1.38
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
3.90
3.60

Institutional Ownership

CompanyInstitutional Ownership
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
98.51%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
78.63%
MorphoSys AG stock logo
MOR
MorphoSys
18.38%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
4.60%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
9.72%
MorphoSys AG stock logo
MOR
MorphoSys
0.05%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
21094.18 million89.84 millionOptionable
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
64059.20 million53.45 millionOptionable
MorphoSys AG stock logo
MOR
MorphoSys
730150.62 million150.55 millionNot Optionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99060.36 million58.54 millionOptionable

Recent News About These Companies

Twist Bioscience (TWST) Receives a Buy from Guggenheim
Twist Bioscience Appoints Trynka Shineman Blake to Board
Twist Bioscience: Headwinds Are Mounting

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Crinetics Pharmaceuticals stock logo

Crinetics Pharmaceuticals NASDAQ:CRNX

$30.99 +0.34 (+1.11%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$31.12 +0.13 (+0.42%)
As of 08/29/2025 06:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Ginkgo Bioworks stock logo

Ginkgo Bioworks NYSE:DNA

$12.71 +0.54 (+4.45%)
Closing price 08/29/2025 03:59 PM Eastern
Extended Trading
$12.52 -0.20 (-1.54%)
As of 08/29/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

MorphoSys stock logo

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)
As of 08/29/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$26.97 +0.38 (+1.43%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$26.65 -0.32 (-1.20%)
As of 08/29/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.